Optimal Therapy for Barrett High Grade Dysplasia



Fig. 22.1
An algorithm reflecting current standard approach for patients with Barrett’s associated neoplasia





A Personal View of the Data


My approach systematically begins with counseling patients on all options of therapy and confirming the diagnosis of dysplasia with our gastrointestinal pathologists. I treat patients with high dose proton pump inhibitors twice daily. I standardly begin with a thorough endoscopic evaluation followed by endoscopic therapy. I utilize advanced imaging modalities that include narrow band imaging and/or confocal laser endomicroscopy to enhance my endoscopic examination to improve my diagnostic yield for biopsies and resections. Treatment for patients with high-grade dysplasia first begins with focal endoscopic mucosal resection of any visible lesions. Then, I treat the remainder of Barrett’s mucosa radiofrequency ablation. Long segments are first treated with circumferential RFA with the balloon device. I treat shorter segments and residual areas with focal RFA. After treatment is completed, I perform surveillance endoscopies with biopsies yearly. I prepare patients with the knowledge that endoscopic treatment may require multiple modalities, multiple sessions, and indefinite surveillance.


Recommendations





  • The presence of dysplasia should be confirmed by a gastrointestinal pathologist. (Evidence quality moderate; weak recommendation)


  • Endoscopic resection of mucosal irregularities in the setting of dysplasia in Barrett’s esophagus should be performed for accurate T staging of neoplasia. (Evidence quality low; weak recommendation)


  • Patients with Barrett’s esophagus with high-grade dysplasia should be managed with endoscopic eradication therapy rather than surveillance. (Evidence quality moderate; weak recommendation)


  • Esophagectomy should be reserved for patients with Barrett’s associated neoplasia with submucosal invasion, lymph node metastasis, or failure of endoscopic therapy (Evidence quality high; strong recommendation)


  • Esophagectomy should be performed at high volume centers. (Evidence quality moderate; weak recommendation)


References



1.

Gillison EW, Powell J, McConkey CC, Spychal RT. Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia. Br J Surg. 2002;89(3):344–8. PubMed PMID: 11872061.PubMedCrossRef


2.

Liu JF, Wang QZ, Hou J. Surgical treatment for cancer of the oesophagus and gastric cardia in Hebei, China. Br J Surg. 2004;91(1):90–8. PubMed PMID: 14716801.PubMedCrossRef


3.

Modiano N, Gerson LB. Barrett’s esophagus: incidence, etiology, pathophysiology, prevention and treatment. Ther Clin Risk Manag. 2007;3(6):1035–145. PubMed PMID: 18516262, Pubmed Central PMCID: 2387291.PubMedCentralPubMed


4.

Fitzgerald RC, Lascar R, Triadafilopoulos G. Review article: Barrett’s oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther. 2001;15(3):269–76. PubMed PMID: 11207503.PubMedCrossRef


5.

Riddell RH, Odze RD. Definition of Barrett’s esophagus: time for a rethink–is intestinal metaplasia dead? Am J Gastroenterol. 2009;104(10):2588–94. PubMed PMID: 19623166.PubMedCrossRef


6.

Tan A, Macrae F. Management of cancer risk in Barrett’s esophagus. J Gastroenterol Hepatol. 2011;26(10):1485–92. PubMed PMID: 21592226.PubMedCrossRef


7.

Spechler SJ. Barrett’s esophagus: the American perspective. Dig Dis. 2013;31(1):10–6. PubMed PMID: 23797117.PubMedCrossRef


8.

Paraf F, Flejou JF, Pignon JP, Fekete F, Potet F. Surgical pathology of adenocarcinoma arising in Barrett’s esophagus. Analysis of 67 cases. Am J Surg Pathol. 1995;19(2):183–91. PubMed PMID: 7832278.PubMedCrossRef


9.

Konda VJ, Ross AS, Ferguson MK, Hart JA, Lin S, Naylor K, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett’s esophagus overestimated? Clin Gastroenterol Hepatol. 2008;6(2):159–64. PubMed PMID: 18096439.PubMedCrossRef


10.

Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, Ajani JA, Swisher SG, et al. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007;31(11):1719–25. PubMed PMID: 18059229.PubMedCrossRef


11.

Lewis JT, Wang KK, Abraham SC. Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for Barrett esophagus: implications for staging of adenocarcinoma. Am J Surg Pathol. 2008;32(4):566–71. PubMed PMID: 18300796.PubMedCrossRef


12.

Chennat J, Konda VJ, Waxman I. Endotherapy for Barrett’s esophagus: which, how, when, and who? Gastrointest Endosc Clin N Am. 2011;21(1):119–33. PubMed PMID: 21112502.PubMedCrossRef


13.

Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523–30. PubMed PMID: 20461069.PubMedCrossRef


14.

Levine DS, Blount PL, Rudolph RE, Reid BJ. Safety of a systematic endoscopic biopsy protocol in patients with Barrett’s esophagus. Am J Gastroenterol. 2000;95(5):1152–7. PubMed PMID: 10811320.PubMedCrossRef


15.

Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia. Am J Gastroenterol. 2000;95(11):3089–96. PubMed PMID: 11095322.PubMedCrossRef


16.

Peters FP, Curvers WL, Rosmolen WD, de Vries CE, Ten Kate FJ, Krishnadath KK, et al. Surveillance history of endoscopically treated patients with early Barrett’s neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus. 2008;21(6):475–9. PubMed PMID: 18430186, Off J Int Soc Dis Esophagus.PubMedCrossRef


17.

Singh R, Anagnostopoulos GK, Yao K, Karageorgiou H, Fortun PJ, Shonde A, et al. Narrow-band imaging with magnification in Barrett’s esophagus: validation of a simplified grading system of mucosal morphology patterns against histology. Endoscopy. 2008;40(6):457–63. PubMed PMID: 18459090.PubMedCrossRef


18.

Kara MA, Peters FP, Rosmolen WD, Krishnadath KK, ten Kate FJ, Fockens P, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37(10):929–36. PubMed PMID: 16189764.PubMedCrossRef


19.

Mannath J, Subramanian V, Hawkey CJ, Ragunath K. Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett’s esophagus: a meta-analysis. Endoscopy. 2010;42(5):351–9. PubMed PMID: 20200809.PubMedCrossRef


20.

Sharma P, Meining AR, Coron E, Lightdale CJ, Wolfsen HC, Bansal A, et al. Real-time increased detection of neoplastic tissue in Barrett’s esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc. 2011;74(3):465–72. PubMed PMID: 21741642, Pubmed Central PMCID: 3629729.PubMedCentralPubMedCrossRef


21.

Chennat J, Konda VJ, Ross AS, de Tejada AH, Noffsinger A, Hart J, et al. Complete Barrett’s eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma–an American single-center experience. Am J Gastroenterol. 2009;104(11):2684–92. PubMed PMID: 19690526.PubMedCrossRef


22.

Wani S, Mathur SC, Curvers WL, Singh V, Herrero LA, Hall SB, et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett’s dysplasia. Clin Gastroenterol Hepatol. 2010;8(9):783–8. PubMed PMID: 20472096, Off Clin Pract J Am Gastroenterol Assoc.PubMedCrossRef

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Dec 30, 2016 | Posted by in CARDIOLOGY | Comments Off on Optimal Therapy for Barrett High Grade Dysplasia

Full access? Get Clinical Tree

Get Clinical Tree app for offline access